The FDA dodged claims from Van­da Phar­ma­ceu­ti­cals that it al­leged­ly vi­o­lat­ed the US Con­sti­tu­tion by rec­om­mend­ing the same drug spec­i­fi­ca­tions for both Van ...

FDA rejected Vanda's Tradipitant NDA, citing insufficient efficacy data from clinical trials and long-term safety concerns. Vanda must address deficiencies, conduct two new trials, and provide ...

Vanda Pharmaceuticals Inc. has a 12-month low of $3.46 and a 12-month high of $6.75. Analysts Set New Price Targets A number of research analysts have recently weighed in on VNDA shares.

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has publicly laid out its reasoning for rejecting Vanda Pharmaceuticals’ ...

Rarely does the FDA pub­licly re­lease its rea­son­ing for re­ject­ing a po­ten­tial new drug. But for DC-based Van­da Phar­ma­ceu­ti­cals’ gas­tro­pare­sis drug, the FDA on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AstraZeneca CFO Aradhana Sarin promised Phase III readouts and revenue growth in 2025 despite ongoing investigations of its Chinese operations. Credit: Bloomberg/ Getty Images AstraZeneca says a ...